The FOXFIRE trial examines the hypothesis that combining radiosensitising chemotherapy ( OxMdG : oxaliplatin , 5-fluorouracil and folic acid ) with Selective Internal Radiation Therapy ( SIRT or radioembolisation ) using yttrium-90 resin microspheres ( SIR-Spheres ; Sirtex Medical Limited , North Sydney , Australia ) as a first-line treatment for liver-dominant metastatic CRC will improve clinical outcomes when compared to OxMdG chemotherapy alone .